Diabetes 54:100-106, 2005
© 2005 by the American Diabetes Association, Inc.
ß-Cell Function Following Human Islet Transplantation for Type 1 Diabetes
Michael R. Rickels1,
Mark H. Schutta1,
James F. Markmann2,
Clyde F. Barker2,
Ali Naji2, and
Karen L. Teff1,3
1 Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
2 Division of Transplantation, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
3 Monell Chemical Senses Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Islet transplantation can provide metabolic stability for patients with type 1 diabetes; however, more than one donor pancreas is usually required to achieve insulin independence. To evaluate possible mechanistic defects underlying impaired graft function, we studied five subjects at 3 months and four subjects at 12 months following intraportal islet transplantation who had received comparable islet equivalents per kilogram (12,601 ± 1,732 vs. 14,384 ± 2,379, respectively). C-peptide responses, as measures of ß-cell function, were significantly impaired in both transplant groups when compared with healthy control subjects (P < 0.05) after intravenous glucose (0.3 g/kg), an orally consumed meal (600 kcal), and intravenous arginine (5 g), with the greatest impairment to intravenous glucose and a greater impairment seen in the 12-month compared with the 3-month transplant group. A glucose-potentiated arginine test, performed only in insulin-independent transplant subjects (n = 5), demonstrated significant impairments in the glucose-potentiation slope (P < 0.05) and the maximal response to arginine (ARmax; P < 0.05), a measure of ß-cell secretory capacity. Because ARmax provides an estimate of the functional ß-cell mass, these results suggest that a low engrafted ß-cell mass may account for the functional defects observed after islet transplantation.
Address correspondencereprint requests to Michael R. Rickels, MD, University of Pennsylvania School of Medicine, Division of Endocrinology, Diabetes,Metabolism, 778 Clinical Research Building, 415 Curie Blvd., Philadelphia, PA 19104-6149. E-mail: mrrickels{at}aol.com

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. R. Rickels, M. Kamoun, J. Kearns, J. F. Markmann, and A. Naji
Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on {beta}-Cell Secretory Capacity
J. Clin. Endocrinol. Metab.,
July 1, 2007;
92(7):
2410 - 2414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Crutchlow, B. Robinson, B. Pappachen, N. Wimmer, A. J. Cucchiara, D. Cohen, and R. Townsend
Validation of Steady-State Insulin Sensitivity Indices in Chronic Kidney Disease
Diabetes Care,
July 1, 2007;
30(7):
1813 - 1818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Eich, O. Eriksson, T. Lundgren, and the Nordic Network for Clinical Islet Transplantat
Visualization of Early Engraftment in Clinical Islet Transplantation by Positron-Emission Tomography
N. Engl. J. Med.,
June 28, 2007;
356(26):
2754 - 2755.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Bertuzzi and C. Ricordi
Prediction of Clinical Outcome in Islet Allotransplantation
Diabetes Care,
February 1, 2007;
30(2):
410 - 417.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Narang and R. I. Mahato
Biological and biomaterial approaches for improved islet transplantation.
Pharmacol. Rev.,
June 1, 2006;
58(2):
194 - 243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Rickels, A. Naji, and K. L. Teff
Insulin Sensitivity, Glucose Effectiveness, and Free Fatty Acid Dynamics after Human Islet Transplantation for Type 1 Diabetes
J. Clin. Endocrinol. Metab.,
June 1, 2006;
91(6):
2138 - 2144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. B. Thornley, M. A. Brehm, T. G. Markees, L. D. Shultz, J. P. Mordes, R. M. Welsh, A. A. Rossini, and D. L. Greiner
TLR Agonists Abrogate Costimulation Blockade-Induced Prolongation of Skin Allografts
J. Immunol.,
February 1, 2006;
176(3):
1561 - 1570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S K Richards, L E Parton, I Leclerc, G A Rutter, and R M Smith
Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo
J. Endocrinol.,
November 1, 2005;
187(2):
225 - 235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Rickels, M. H. Schutta, R. Mueller, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff
Islet Cell Hormonal Responses to Hypoglycemia After Human Islet Transplantation for Type 1 Diabetes
Diabetes,
November 1, 2005;
54(11):
3205 - 3211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Ryan, B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R.T. Lakey, and A.M. J. Shapiro
Five-Year Follow-Up After Clinical Islet Transplantation
Diabetes,
July 1, 2005;
54(7):
2060 - 2069.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Diabetes Association.
|
|
| |
|